| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4045 | Pd-160725 Isethionate | AMPA receptor antagonist |
|
| DCC4046 | Pd-161989 Isethionate | AMPA receptor antagonist |
|
| DCC4047 | Pd-174494 | Novel, potent, and selective NR1/2B NMDA receptor antagonist |
|
| DCC4048 | P-d1ago | Novel cell specific photoswitchable agonist for reversible control of endogenous dopamine receptors |
|
| DCC4049 | Pd26-tl07 | Novel selective inhibitor of STAT3 phosphorylation, binding to the SH2 domain of STAT3, exhibiting remarkable antiproliferative activity against three cancer cell lines (HCT-116, SW480 and MDA-MB-231) |
|
| DCC4050 | pda-66 | Novel inducer of mitotic arrest and apoptosis in human progenitor and cancer cells |
|
| DCC4051 | Pdd4091 | Novel G6PD inhibitor |
|
| DCC4052 | Pde5-in-42 | Potent and selective second-generation phosphodiesterase type 5 (PDE5) inhibitor |
|
| DCC4053 | Pde7 Inhibitor S14 | Novel cell-permeable PDE7 inhibitor, targeting the cyclic adenosine monophosphate (cAMP)/cAMP-response element binding protein (CREB) pathway, exerting neuroprotection in an Alzheimer's disease (AD) model |
|
| DCC4054 | Pde9-in-16 | Novel selective PDE9 inhibitor with strong antioxidant activity, inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer’s disease |
|
| DCC4055 | Pde9-in-2 | Novel Potent, Selective, and Orally Bioavailable Inhibitor against Phosphodiesterase-9 (PDE9) |
|
| DCC4056 | P-decylaminophenol | Novel inhibitor of melanogenesis |
|
| DCC4057 | Pdf Inhibitor M-2 | Novel Peptide Deformylase (PDF) Inhibitor |
|
| DCC4058 | Pdi-in-p1 | Protein disulfide isomerase (PDI) inhibitor |
|
| DCC4059 | Pd-l1 Degrader F4 | Novel PD-L1 degrader, showing 66.99% degradation activity at 20 μM with no calcium blocking effect, strengthening the T cell-mediated killing of tumor cells |
|
| DCC4060 | Pd-l1 Degrader P22 | Novel PROTAC dual inhibitor and degrader of PD-L1, inhibiting PD-1/PD-L1 interaction with IC50 of 39.2 nM in an HTRF binding assay |
|
| DCC4061 | Pd-l1 Inhibitor L7 | Novel Potent PD-L1 Inhibitor (IC50 1.8 nM), binding to human PD-L1 (hPD-L1) with a KD value of 3.34 nM, without showing any binding to hPD-1, blocking PD-1/PD-L1 interaction with an EC50 value of 375 nM |
|
| DCC4062 | Pdsinh-c01 | Novel pendrin inhibitor, inhibiting Cl-/anion exchange mediated by mouse pendrin without affecting other major kidney tubule transporters |
|
| DCC4063 | Peg-vtx | Novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML) |
|
| DCC4064 | Pelorol | Activator of SHIP-1 |
|
| DCC4065 | pemedolac | Cyclooxygenase Inhibitor and Prostagladin Synthase Inhibitor |
|
| DCC4066 | Penb-l-glutamate | Novel caged glutamate |
|
| DCC4067 | Penclomedine | Antineoplastic agent, alkylating and crosslinking DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis |
|
| DCC4068 | Penicillic Acid | Mycotoxin with antibiotic and carcinogenic activity |
|
| DCC4069 | penicillin K | Antibiotic, a natural penicillin, synthesized in vitro by incubating (S-octanoyl)glutathione, 6-APA and AT |
|
| DCC4070 | Penindolone | Novel potent and broad-spectrum anti-influenza A virus (anti-IAV) activities with low risk of inducing drug resistance |
|
| DCC4071 | Pentamidine Dimesylate | Inhibitor of calcium-dependent complex formation with p53 [(Ca)S100B-p53] in malignant melanoma (MM), restoring p53 tumor suppressor activity in vivo |
|
| DCC4072 | Peptide 1018 | Innate defense regulator, target stringent response-controlled virulence in a Pseudomonas aeruginosa murine cutaneous infection model |
|
| DCC4073 | Peptide 4f | ApoA-I/HDL mimetic peptide, efficiently crossing the blood-brain barrier and modulating amyloid beta distribution between brain and plasma |
|
| DCC4074 | Peptide P9r | Broad-spectrum virus- and host-targeting peptide, inhibiting coronaviruses and other respiratory viruses |
|
